

## Aflibercept (VEGF Trap)

|                  |   |
|------------------|---|
| <b>Cat. No.:</b> | HY-108801A  |
| <b>CAS No.:</b>  | 862111-32-8   |
| <b>Target:</b>   | VEGFR   |
| <b>Pathway:</b>  | Protein Tyrosine Kinase/RTK   |
| <b>Storage:</b>  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

#### Description

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for the research of age-related macular degeneration (AMD) and cardiovascular disease<sup>[1][2][3]</sup>.

### REFERENCES

- [1]. Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. *Br J Ophthalmol*. 2014 Oct;98(10):1448-52.
- [2]. Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. *Acta Pharmacol Sin*. 2021 Sep;42(9):1437-1448.
- [3]. Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. *Stroke*. 2021 Aug;52(8):2637-2648.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA